News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMPH buy 42.3299
https://finance.yahoo.com/quote/AMPH/profile?p=AMPH
https://www.barchart.com/stocks/quotes/AMPH
https://finviz.com/quote.ashx?t=AMPH
https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=AMPH
https://stockcharts.com/c-sc/sc?chart=AMPH,uu[e,a]dhclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b
https://www.barchart.com/etfs-funds/quotes/AMPH/technical-chart?plot=CANDLE&volume=toAMPH&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=TREND&sym=AMPH&grid=1&height=500&studyheight=100&timeframe=2%20Months
normal chart
log chart
normal chart
log chart
AMPH 50/200sma crossed here...Nice bullish sign.
AMPH 30 This chart has gotten a little ahead of it self . IMHO
AMPH M
AMPH D
good posting on AMPHASTAR partner.
Moved from the MNKD Board.
Ha Ha Ha we are trying to be a POS penny stock like the ones you follow. Perhaps our bad Karma will get us to that position. But I am betting that won't happen. Perhaps today its ugly but let's see where we are this time next year.
A good Doctor had these comments on another message board. Perhaps he see's the future of Diabetic treatment.
Let me give you the perspective of a primary care physician. Sanofi tried for a long time to push Apidra to us. There was not enough of a difference between it and our standards, Novolog and Humalog, to convince many to change, so the sales with primary care docs fell flat. As a result Sanofi now positions Apidra as the preferred insulin for pumps and they have been somewhat successful with that marketing strategy. Afrezza on the other hand is a totally different product. It is inhaled, not just another shot. And it does not come with a complicated delivery device like Exubera did. Have you ever seen the delivery device for Exubera? It was extremely complicated. Despite being instructed in its use on several occasions I could see that it was far too complicated for the average patient and therefore never prescribed Exubera. The Dreamboat on the other hand is extremely simple and requires less instruction time than even the simplest of the insulin pens. And yes, I have actually had a Dreamboat in my hands so I know what I am talking about. This will save me time in my office, something that is going away quickly as the practice of medicine becomes more and more complex thanks to all the regulations from Uncle Sam and the other insurance companies. The reason that Exubera failed was the delivery device first of all and the fact that it was in milligrams, not units (and the mg to unit conversion was not even 1:1, too complicated). All a patient has to do with the Dreamboat is open it up, insert a cartridge, close it, and breathe in deeply. And every 2 weeks just drop the used Dreamboat in a trash can and pull out a fresh clean Dreamboat. No cleaning, no replacing parts, etc, etc, etc that were required with the Exubera bong. And it will fit in the pocket of any man, something that a man could actually do with the Exubera device but resulted in him getting all sorts of crude comments from those around him.
For those of you who think for whatever reason that Afrezza will fail you should think again. I have been doing this a long, long time. This is going to be a game changer. In diabetes for now. But in many medical fields in the coming years. I am not pumping as you call it on this board, I am simply looking at what goes on in an average primary care practice. I am sure that there will be criticisms of this post. That seems to occur for most posts that look at the good side of Afrezza. Bring it on. And mark my word. And mark this post. (Last 2 sentences thrown in on purpose to raise the hair on the back of the necks of those who get all upset when they read those words.)
I look forward to my investment returning me a a great increase in PPS and the game changer it brings to the Diabetic community. So if MannKind is not at $15.00 this time next year its a failure. If the company is not purchased by SNY for $30.00 per share next year its a failure. But at least I have enjoyed the fact that long term this product will benefit Millions of diabetics in the USA and the world. Mark my word.
Mannkind is not a plane crash. 
